Bioswellix^®

Resveratrol, Curcumin, Boswellia and Green tea catechins were reviewed as natural immunomodulators with an excellent safety profile and a promising potential for treating inflammations, such as IBD (inflammatory bowel disease).

Clarke JO, Mullin GE.
A review of complementary and alternative approaches to immunomodulation.

http://www.ncbi.nlm.nih.gov/Abstract

Ammon HP.
Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases

http://www.ncbi.nlm.nih.gov/Abstract

Ammon HP, Safayhi H, Mack T, Sabieraj J.
Mechanism of antiinflammatory actions of curcumine and boswellic acids.

http://www.ncbi.nlm.nih.gov/Abstract

Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Muller S, Senninger N, Russell J, Jauch J, Bergmann J, Granger DN, Krieglstein CF.
Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis.

http://www.ncbi.nlm.nih.gov/Abstract

Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R.
Therapy of active Crohn disease with Boswellia serrata extract H 15

http://www.ncbi.nlm.nih.gov/uids=11215357&dopt=Abstract

Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke R, Safayhi H, Ammon HP.
Effects of gum resin of Boswellia serrata in patients with chronic colitis.

http://www.ncbi.nlm.nih.gov/uids=11488449&dopt=Abstract

Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, Ammon HP.
Effects of Boswellia serrata gum resin in patients with ulcerative colitis.

http://www.ncbi.nlm.nih.gov/uids=9049593&dopt=Abstract

Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, Ammon HP.
Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study.

http://www.ncbi.nlm.nih.gov/uids=12470437&dopt=Abstract

Huang MT, Badmaev V, Ding Y, Liu Y, Xie JG, Ho CT.
Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid.

http://www.ncbi.nlm.nih.gov/uids=11455013&dopt=Abstract

Kimmatkar N, Thawani V, Hingorani L, Khiyani R.
Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial.

http://www.ncbi.nlm.nih.gov/uids=12622457&dopt=Abstract

Krieglstein CF, Anthoni C, Rijcken EJ, Laukotter M, Spiegel HU, Boden SE, Schweizer S, Safayhi H, Senninger N, Schurmann G.
Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis.

http://www.ncbi.nlm.nih.gov/uids=11355324&dopt=Abstract

Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B.
Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study.

http://www.ncbi.nlm.nih.gov/Abstract

Madisch A, Miehlke S, Eichele O, Mrwa J, Bethke B, Kuhlisch E, Bästlein E, Wilhelms G, Morgner A, Wigginghaus B, Stolte M.
Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial.

http://www.ncbi.nlm.nih.gov/&dopt=Abstract

Reichling J, Schmokel H, Fitzi J, Bucher S, Saller R.
Dietary support with Boswellia resin in canine inflammatory joint and spinal disease.

http://www.ncbi.nlm.nih.gov/uids=12622457&dopt=Abstract

Sharma S, Thawani V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R.
Pharmacokinetic study of 11-Keto beta-Boswellic acid.

http://www.ncbi.nlm.nih.gov/uids=12622457&dopt=Abstract

Sterk V, Buchele B, Simmet T
Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers.

http://www.ncbi.nlm.nih.gov/uids=12622457&dopt=Abstract

Syrovets T, Gschwend JE, Buchele B, Laumonnier Y, Zugmaier W, Genze F, Simmet T.
Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo.

http://www.ncbi.nlm.nih.gov/Abstract

Winking M, Sarikaya S, Rahmanian A, Jodicke A, Boker DK.
Boswellic acids inhibit glioma growth: a new treatment option?

http://www.ncbi.nlm.nih.gov/uids=10894362

INTERPHARMA PRAHA, a.s., Komoranska 955, 143 10 Praha 12, Czech Republic

Business Development: 00420-241 773 242

Secretariat: 00420-241 773 242, Fax: 00420-241 773 235

 

Email: